Print

AVEG 024

A Randomized, Placebo Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120, Combined with MF59

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) September 18, 1995
rgp120/HIV-1 SF-2 Env gp120 B SF-2
rgp120/HIV-1 SF-2 Protein
MF59
USA 30
NCT00000832
http://www.clinicaltrials.gov/ct2/show/NCT00000832